Welcome to the iCAD Investors Page
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.
The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".
Featured Financial Press Releases
May 22, 2017
iCAD To Participate In Two Upcoming Investor Conferences
Featured Events and Webcasts
June 6, 2017
3:00 pm PT
7th Annual LD Micro Invitational Conference Details
May 2, 2017
4:30 pm ET
iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2
March 15, 2017
9:30 am PT / 12:30 pm ET
March, 6, 2017
iCAD to Present at the 29th Annual ROTH Conference
Berry & Company Public Relations, LLC
CAD is committed to corporate sustainability and to making a difference for our environment.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.
© 2017, iCAD Inc. All rights reserved. iCAD, the iCAD logo and Never Stop Looking is a trademark of iCAD, Inc.
Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.